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Abstract
 
Infection by the gastroduodenal pathogen 
 
Helicobacter pylori
 
 elicits a complex
immunologic response in the mucosa involving neutrophils, plasma cells,
eosinophils, and lymphocytes, of which T cells are the principal orchestrators of
immunity. While so-called classical T cells (e.g. T-helper cells) that are activated
by peptide fragments presented on antigen-presenting cells have received
much attention in 
 
H. pylori 
 
infection, there exists a diverse array of other T cell
populations that are potentially important for the outcome of the ensuing
immune response, some of which have not been extensively studied in 
 
H. pylori
 
infection. Pathogen-specific regulatory T cells that control and prevent the
development of immunopathology associated with 
 
H. pylori 
 
infection have been
investigated, but these cells can also benefit the bacterium in helping to prolong
the chronicity of the infection by suppressing protective immune responses.
An overlooked T cell population, the more recently described Th17 cells, may
play a role in 
 
H. pylori-
 
induced inflammation, due to triggering responses that
ultimately lead to the recruitment of polymorphs, including neutrophils. The
so-called innate or unconventional T cells, that include two conserved T cell
subsets expressing invariant antigen-specific receptors, the CD1d-restricted
natural killer T cells which are activated by glycolipids, and the mucosal-
associated invariant T cells which play a role in defense against orally acquired
pathogens in the intestinal mucosa, have only begun to receive attention. A
greater knowledge of the range of T cell responses induced by 
 
H. pylori 
 
is
required for a deeper understanding of the pathogenesis of this bacterium and
its ability to perpetuate chronic infection, and could reveal new strategies for
therapeutic exploitation.
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Helicobacter pylori
 
 is recognized as the causative agent of
active chronic gastritis and is the predominant cause of
peptic ulceration, i.e. gastric and duodenal ulcers [1].
Additionally, 
 
H. pylori
 
 is a cofactor in the development of
gastric cancer, both adenocarcinoma and mucosa-associated
lymphoma, and therefore has been designated as a class I
carcinogen by the World Health Organization [2]. Overall,
10–15% of 
 
H. pylori-
 
infected individuals develop peptic
ulcers and 1–2% develop gastric adenocarcinoma [3].
Persistence of infection for years or even decades is a
central hallmark of the interaction between 
 
H. pylori
 
 and
untreated humans [1]. As there is associated gastric
inflammation, the immune response to 
 
H. pylori
 
 can play
an important role in pathogenesis. The focus of the present
paper is to review the role of conventional, regulatory
and unconventional T cells in the response to 
 
H. pylori
 
infection, placed in the context of the overall immunologic
response to this infection, and to highlight the state of
knowledge as well as emerging issues on the nature of the
T cell response.
 
Characteristics of the Immunologic 
Response to 
 
H. pylori
 
H. pylori
 
 colonization of the gastric mucosa elicits a complex
immune response initiating innate as well as adaptive
immune responses [1,4–7]. It is well-established that there
is a significant influx of neutrophils, lymphocytes, plasma
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cells, and eosinophils into the gastric mucosa in 
 
H. pylori
 
-
associated gastritis [8]. Ultimately, despite the development
of a prominent localized immune response, leading to active
inflammation in the gastric mucosa [3], the bacterium
is rarely eliminated and infections can last for decades
if left untreated [9]. It is important to note that a large
proportion of infecting 
 
H. pylori 
 
(85%) occupy a unique
ecological niche within the gastric mucus, as well as on the
surface of gastric epithelial cells (10%) and at intercellular
junctions (5%) [10,11]. By residing within this environ-
ment, the bacterium may minimize recognition by the
innate immune system and evade phagocytosis because
neutrophils and macrophages do not appear to traverse
the gastric epithelium into the mucus layer [12]. On
the one hand, the duration of immune recognition of
 
H. pylori
 
, but potential lifelong colonization on the other
hand, demonstrate the effectiveness of the bacterium to
evade, dampen or inhibit host responses contributing to
immunity [13]. Importantly, among all individuals infected
with 
 
H. pylori
 
, 15–20% will develop more severe forms
of gastric disease including peptic ulcers and cancer [14].
Thus, while the interplay between the virulence factors
of 
 
H. pylori
 
 and the host immune responses is likely to
contribute to the outcome of infection, these responses are
largely ineffective in eliminating the bacterium.
 
Inﬂammatory Response to 
 
H. pylori
 
Early in infection, 
 
H. pylori
 
 induces production of the
chemokines RANTES (Regulated on Activation, Normal T
Expressed and Secreted, also called CCL5), GRO-
 
α
 
, MIP-1
 
α
 
,
ENA 78, and MCP-1, as well as secretion of the cytokines
interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha
(TNF-
 
α
 
) [15]. The production and expression of these
proinflammatory agents is controlled by the transcription
factor, nuclear factor-kappaB (NF-
 
κ
 
B), and the initial
trigger is likely to be mediated by epithelial cells [16].
Several 
 
H. pylori 
 
membrane proteins encoded within the
 
cag
 
 pathogenicity island (PAI), which also contains the
cytotoxin-associated gene A (
 
cagA
 
), induce activation of
NF-
 
κ
 
B and up-regulation of mRNA of the neutrophil
chemotactic chemokine IL-8 [17]. Moreover, epithelial
cells infected with CagA
 
+
 
 
 
H. pylori
 
 strains activate the early
transcription factor AP-1 which is known to stimulate
IL-1, IL-6, and MCP-1 production [18]. Consistent with
this, Masamune et al. [19] showed that direct contact
of epithelial cells with 
 
H. pylori
 
 results in C
 
2
 
-ceramide
production with subsequent activation of NF-
 
κ
 
B and IL-8.
The list of 
 
H. pylori
 
 products which trigger or exacerbate
mucosal inflammation continues to grow. Host responses
to the urease molecule, lipopolysaccharide (LPS), 
 
H. pylori
 
heat-shock proteins (Hsp60 and Hsp70), and the vacuolat-
ing toxin (VacA) include development of marked antral
gastritis, severe mucosal damage [20,21], up-regulation
of proinflammatory cytokine production [20,22], and
altered epithelial barrier function [23] with changed
uptake of macromolecules [24]. Therefore, 
 
H. pylori 
 
and its
products induce a significant inflammatory response in the
infected mucosa contributing to the pathology associated
with infection.
 
Innate Immune Response to 
 
H. pylori
 
Innate immune responses against infection depend on
recognition of invariant structures or so-called pathogen-
associated molecular patterns (PAMPs) on microorganisms
[25]. These PAMPs include microbial components such as
LPS, peptidoglycan, flagellin, double-stranded RNA, and
zymosan. The receptors on epithelial and innate immune
cells, e.g. macrophages, neutrophils, and natural killer
cells (NK cells), that recognize these PAMPs are termed
pathogen-recognition molecules, examples of which are the
Toll-like receptors (TLRs) [25] and the Nod proteins [26].
There have been several studies investigating innate
immune responses to 
 
H. pylori
 
 that have focused on TLR4
[27–29], which is generally considered the pathogen-
recognition molecule for Gram-negative bacterial LPS,
ranging from the activation of TLR4 expression in gastric
epithelial cells by 
 
H. pylori
 
 [29] to the role of TLR4 in the
proapoptotic action of LPS [27] and the interaction of
 
H. pylori 
 
LPS with TLR4 influencing superoxide metabo-
lism in gastric pit cells [28]. More recently, studies have
also focused on TLR2 and TLR5 which have been deduced
to be the pathogen-recognition molecules for bacterial
lipopeptides and flagellin, respectively [30]. In particular,
NF-
 
κ
 
B activation in response to 
 
H. pylori
 
 is decreased by
transfection with dominant negative constructs for TLR2
and TLR5 [31], thus indicating the importance of these
immune receptors in immune recognition. TLR4 mRNA
has been detected in human gastric epithelial cell lines [29],
although using these cell lines signaling through TLR4 in
mediating innate responses to 
 
H. pylori 
 
was concluded not
to be important [32]. On the other hand, such cells lines
can lack MD-2 expression which is a critical cofactor for
TLR4-mediated signaling [31]. This was deduced to explain
the observed lack of significance of TLR4 signaling in
such cell lines, and furthermore, examination of biopsy
specimens showed TLR4-dependent signaling during 
 
H. pylori-
 
associated infection and the essential role of MD-2 in this
signaling [33]. Likewise, TLR4-dependent signaling with
CD14, which has been considered important in loading
LPS onto TLR4, was reported to be absent in primary
human gastric epithelial cells [32]. However, LPS presen-
tation to gastric epithelial cells would occur in a serum-
free, and hence CD14-free, environment in the stomach.
In contrast, other investigators found TLR4 expression on
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gastric pit cells of biopsies from guinea pigs [28] and
humans [33] that is capable of sampling 
 
H. pylori 
 
LPS in the
stomach environment. Thus, in contrast to gastric cell lines
in vitro, TLR4-mediated signaling can occur in vivo.
Importantly, compared to other Gram-negative bacteria,
 
H. pylori
 
 LPS is a poor activator of the innate immune
response [34–36]. In accord with this low activity, 
 
H. pylori
 
LPS exhibits poor binding to serum-associated LPS-
binding protein and CD14 [37] but also to TLR4 [38]. The
predominant TLR response to 
 
H. pylori 
 
bacteria (but also
to 
 
Helicobacter felis
 
 and 
 
Helicobacter hepaticus
 
 whole cells)
is not mediated by TLR4, which contrasts with most
Gram-negative bacteria that preferentially activate TLR4
by their potent LPS ligands, but rather by TLR2 [39]. Using
TLR-transfected cell lines, Smith et al. [31] reported that
 
H. pylori
 
 LPS was a TLR2 agonist, whose activation was
enhanced by CD14, and deduced that TLR2 binding was
likely based on similarities between the structure of the
lipid A component of 
 
H. pylori 
 
LPS and that of 
 
Porphyromonas
gingivalis 
 
lipid A whose LPS unusually is considered to be
a TLR2, not a TLR4, ligand [40]. However, Mandell et al.
[39] using highly pure LPS from 
 
H. pylori
 
 clinical isolates,
that had been chemically assayed to be free of lipopeptides
and other contaminants, found TLR4- but not TLR2-
mediated cytokine production by TLR-transfected cell lines
and macrophages from knockout mice. Likewise, another
study demonstrated that 
 
H. pylori
 
 acted via TLR4 to stimulate
reactive oxygen production from guinea pig gastric pig
cells [28]. The discrepancies between these findings can
be attributed to the presence of TLR2-activating con-
taminants in LPS test preparations [38], which have also
contributed to inconsistencies in results when investigating
other ligand–immune receptor interactions [41], as well
as to differences in LPS dosages between the studies
(nanogram [39] vs. microgram [31]). The latter has been
confirmed in an independent study [42]. Hence, although
the predominant TLR response to 
 
H. pylori
 
 is TLR2-mediated,
this response is not mediated by 
 
H. pylori
 
 LPS, rather
 
H. pylori
 
 LPS is a TLR4 agonist with low activity.
Notwithstanding this, the failure to detect TLR2 expres-
sion in the stomach (both in humans [39] and in mice [43]),
compared to the detection of TLR4 on gastric pit cells (in
guinea pigs [28] and humans [33]) has important implica-
tions for 
 
H. pylori
 
 colonization. In the absence of TLR2 in
the gastric environment, the interaction of 
 
H. pylori
 
 LPS
with TLR4 can be critical to the early detection of 
 
H. pylori
 
by the innate immune system [44] and would influence
colonization [45]. Accordingly, upon initial infection of the
gastric mucosa, 
 
H. pylori
 
 may be weakly recognized by
interaction of its LPS with TLR4 on gastric cells. Thus,
 
H. pylori
 
 by expressing an LPS with very weak TLR4 agonist
activity and colonizing a TLR2-deficient environment can
escape detection and elimination by the immune response
initially. Consistent with this evasion of immune detection,
though functional TLR5 is expressed in the adult stomach
[46], and TLR5 is considered to bind and respond to
bacterial flagellins, 
 
H. pylori 
 
flagellins FlaA and FlaB induce
a very low activation of TLR5-mediated responses [47].
Overall, although 
 
H. pylori
 
 molecules interact with TLR4
and TLR5 that are expressed in the stomach, these inter-
actions are of low activity, thereby allowing initial 
 
H. pylori
 
colonization. Subsequently, with the progression of longer
term infection, a substantial inflammatory response to
 
H. pylori 
 
can develop after the infiltration of TLR2-expressing
granulocytes and monocytes into the infected gastric
mucosa.
Another family of pathogen-recognition molecules,
the Nod proteins, appear to have a more central role in
mediating innate immunity against 
 
H. pylori
 
. Two members
of this protein family, Nod 1 (also called CARD4) and Nod2
(also called CARD15), are involved in the intracellular
recognition of bacterial muropeptides derived from
bacterial peptidoglycan but differ in their specificity; Nod1
recognizes a bacterial muramyl tripeptide [48], Nod2 a
muramyl dipeptide [41]. Of particular importance, NF-
 
κ
 
B
and IL-8 production in epithelial cells has been shown to
be dependent on signaling through intracytoplasmic Nod1
recognition of muropeptides from 
 
H. pylori
 
 peptidoglycan
[49]. Thus, in innate immune recognition of 
 
H. pylori 
 
by
gastric epithelial cells, recognition by Nod1 is likely more
important than by TLRs. This is supported by a mouse
model of 
 
Helicobacter
 
 infection where inhibition of Nod1-
mediated activation of the innate immune system resulted
in a significantly greater colonization density. The 
 
H. pylori
 
muramyl tripeptide is delivered intracellularly by the
type IV secretion system-encoding 
 
cag 
 
PAI [49], and this
represents one mechanism by which 
 
cag 
 
PAI-positive
strains elicit a more vigorous inflammatory response and,
in part, explains why these strains are associated with more
aggressive disease symptoms, e.g. gastric cancer [38].
A further PAMP recognition receptor of importance
in the innate immune response to 
 
H. pylori 
 
is surfactant
protein-D (SP-D) [12]. SP-D is a collagenous glycoprotein
that contains trimeric arrays of C-type (calcium-dependent)
lectin domains and which belongs to a family of proteins
called the collectins [50]. Although originally identified in
the lungs as a component of surfactant [51] and associated
with type II cells and Clara cells [52], expression of SP-D
also occurs at the gastric luminal surface and within gastric
pits [53]. Infection with 
 
H. pylori 
 
up-regulates expression
of SP-D, which colocalizes with 
 
H. pylori 
 
organisms, in
patients with gastritis [53]. Moreover, the influence of SP-D
binding on 
 
Helicobacter 
 
colonization has been demonstrated
in a SP-D-deficient mouse model [54]. In vitro studies have
shown that SP-D binds and agglutinates 
 
H. pylori
 
 cells in a
lectin-like manner [12,53], and results in considerable
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reduction in bacterial motility, as determined on the basis
of curvilinear velocity in microscopic video tracking
experiments [53]. Bacterial aggregation by SP-D can reduce
susceptibility to infection and colonization density, as
observed in the SP-D-deficient mouse model [54], by its
effect on bacterial motility, as well as influencing phago-
cytosis and bacterial membrane permeability, and hence
survival [12]. The 
 
H. pylori 
 
ligand for SP-D binding has been
identified as LPS [53], though there is marked variation
in the avidity of binding among strains and their LPSs
[53,55], potentially reflecting different structural properties.
Of particular interest, a single 
 
H. pylori
 
 strain can produce
variants with modified LPS O-chain structures that escape
or avoid SP-D agglutination [55]. Upon examination of
gastric biopsies, SP-D-binding isolates predominate in the
mucus layer compared to the tissue component [12,55].
Although the SP-D-susceptible forms have a more rapid
growth kinetics, they would be more readily cleared from
the mucosa, but on the other hand, the SP-D-resistant forms
with a lower growth rate would have a selective advantage
to avoid SP-D binding and, hence, interact with gastric
tissue leading to inflammation and potential nutrient release
[55]. However, reversible switching of O-chain structure
occurs in the absence of SP-D selective pressure in vitro [55],
suggesting that SP-D evasion is mediated by phase-variable
mechanisms [56]. Thus, the ability of the bacterium to
evade SP-D binding would allow interaction with the
gastric epithelium and colonization to become established.
Collectively, although SP-D binding can play an important
role in initial defense against the infection, once colonization
becomes established and bacterial interaction occurs with
gastric epithelial cells, the Nod1-mediated interaction would
appear more important for the induction of the inflamma-
tory response than TLR4- or TLR5-mediated responses.
 
Antigen-Presenting Cells in 
 
H. pylori
 
 Infection
 
There are several populations of immune cells localized
within the gastric mucosa that through molecular cross-
talk contribute to 
 
H. pylori
 
–host interactions [3,7]. Thus, in
addition to epithelial cells, macrophages and dendritic
cells reside within the gastric mucosal layers of 
 
H. pylori
 
-
infected individuals. 
 
H. pylori 
 
infection results in up-
regulation of MIP-3
 
α
 
 gene expression in gastric epithelial
cells, thus inducing an influx of mononuclear cells into
the lamina propria of the mucosa [57]. Nonetheless, these
cells may be functionally impaired, as 
 
H. pylori 
 
can inhibit
phagocytosis by macrophages [58,59], though the mole-
cular mechanism has not been elucidated to date, but
ultimately results in decreased and altered processing of
 
H. pylori 
 
antigens. Because the peptide-dependent activation
of cells associated with the adaptive immune response
(B and T cells) requires macrophage and dendritic cell
presentation of 
 
H. pylori-
 
processed antigens, this has major
importance for the outcome of the developing immune
response against the bacterium, although the responses of
these cells to 
 
H. pylori
 
 live bacteria and 
 
H. pylori
 
-derived
products are complex. NF-
 
κ
 
B activation by macrophages/
monocytes, and consequently, IL-12 induction that
influences T cell differentiation, appears independent of
the 
 
H. pylori cag
 
 PAI [60] but in contrast to epithelial cells
[32], it predominantly involves CD14 and TLR4 [61].
Moreover, 
 
H. pylori
 
 LPS stimulates NF-
 
κ
 
B and IL-8 pro-
duction by macrophages/monocytes in a CagA-independent
manner [62], whereas NF-
 
κ
 
B activation in epithelial cells
by 
 
H. pylori
 
 is peptide-dependent [63]. Overall, activation
of antigen-presenting cells not only plays a role in pro-
cessing and presentation of 
 
H. pylori
 
 antigens to cells of
the adaptive immune response but also influences their
differentiation due to the release of cytokines, e.g. IL-12
induction influences T-cell differentiation.
 
Adaptive Immune Responses to 
 
H. pylori
 
The other main arm of immunity, the adaptive immune
response is characterized by the presence of T and B cell
populations which bear highly diverse antigen-specific
receptors. T cells are responsible for cell-mediated immunity
and, thus, are central to and promote activation of many
other immune cells and killing virally infected and target
tumor cells, whereas B cells produce antibodies in humoral
immunity. Initially, it was assumed that a protective
immune response against 
 
H. pylori would be predominantly
mediated by antibodies, based on analogy with other
mucosal infections [1] and correlations between anti-
H. pylori antibodies in breast milk and absence of H. pylori
in breast-fed children [64]. Consistent with this deduction,
studies have shown that antibodies can influence colon-
ization by H. pylori in animal experiments [65] and be
bactericidal [66], and can effectively prevent infection and
reduce colonization in Helicobacter animal models in mice
[67] and gerbils [68]. Nevertheless, it has become apparent
that the humoral response is only marginal for the
induction of protective immunity [1], and it is cellular
rather than humoral immunity that has been deduced to
play the principal role in sterilizing immunity [69–72].
For example, Ermak et al. [69] reported that protection
of mice against H. pylori infection by immunization with
urease antigen is dependent on major histocompatibility
complex (MHC) class II-restricted cell-medicated mechanisms
and that antibody responses to urease are not required for
protection. Likewise, H. pylori immunization had no effect
on the bacterial infection level in MHC class II-deficient
mice [70], but did reduce colonization in B cell-deficient
mice [71]. Moreover, Eaton et al. [72] showed that
enhanced cellular immune responses in recipient SCID
O’Keeffe and Moran T cells and H. pylori
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mice after splenocyte transfer allowed clearing of H. pylori
infection and resolution of gastritis.
In summary, although there have been numerous
investigations of the proinflammatory responses to
H. pylori, as well as the innate and humoral immune
responses to the microorganism, and which have been
shown to contribute to H. pylori infection outcome, the
remainder of this review will focus on the role of T cells
and related cell lineages in immune responses to H. pylori
to highlight their importance in the context of these other
immune responses.
Classical T cell Immune Response
T cells are the principal orchestrators of adaptive immunity
which undergo clonal expansion upon recognition of
peptide fragments complexed with MHC class I or II mole-
cules on antigen-presenting cells. Classically, conventional
T cells have been considered to include CD4+ T-helper
cells that recognize peptides complexed to MHC class II
molecules and, through cytokine secretion, promote the
immune response including B cell differentiation, whereas
CD8+ T-cytotoxic cells can recognize peptides complexed
to MHC class I molecules and promote killing of cells
infected by intracellular pathogens [73]. Nevertheless,
there are a variety of other T cell subsets that contribute
to and regulate the immune response to infection. Overall,
H. pylori is capable of stimulating T cell activity, and a
variety of bacterial antigens have been implicated in the
process [74,75].
In the effector phase of an immune response, different
T cell subsets, called T-helper-1 (Th1) and T-helper-2 (Th2)
cells, expand (Table 1). Th1 cells promote proinflammatory
cell-mediated immunity through production of cytokines
such as interferon-gamma (IFN-γ) and TNF-α, whereas
Th2 cells promote humoral immunity by secreting IL-4,
IL-5, and IL-13 that induce B cells to produce antibodies
[73,76] (Fig. 1). Although Th1- and Th2-type cytokine
profiles were originally identified through analysis of
murine T cell clones [77], there is evidence that chronically
stimulated human T-cells are polarized into Th1 or Th2
patterns of cytokine synthesis [78], the so-called Th1/Th2
paradigm. There are many genetic and environmental
factors which influence the differentiation of Th1 and
Th2 cells. IL-12, IL-18, and interferons favor Th1-cell
development, whereas IL-4 is a potent stimulus for Th2-
cell development [79].
H. pylori and the Th1/Th2-Cell Paradigm
To date, studies investigating the nature of the immune
response to H. pylori have largely focused on classical T
cells which are found in abundance in the antrum of the
majority of H. pylori-infected donors [80]. In H. pylori
infection, T cells participate in promoting local inflam-
mation, can be partially protective, and/or are involved in
regulating the immune response to H. pylori. Early studies
that investigated T cell responses to H. pylori showed
that, in healthy controls as well as in H. pylori-infected
individuals, peripheral blood-derived T cells proliferated in
response to stimulation with H. pylori-derived antigens,
including whole bacterium [81] and crude membranes or
cytoplasmic proteins [82]. However, others have shown
that memory T cells derived from peripheral blood of
infected individuals respond less to stimulation with H. pylori
Figure 1 T-helper and regulatory T-cell differentiation with associated
cytokine proﬁles. T-helper cells differentiate from immature T-cell popu-
lations (Th0 cells) in the thymus. Under the inﬂuence of local cytokines, a
naïve Th0 cell differentiates into a T-helper-1 (Th1) cell that secretes
interferon-gamma (IFN-γ), interleukin- (IL-) 2, and lymphoxin-alpha (LT-α), or
a T-helper-2 (Th2) cells that secretes IL-4, IL-5, IL-6, IL-10, and IL-13, or into
regulatory T cells (Treg cells) that secrete IL-10 or tumor growth factor-beta
(TGF-β) (Th3 cell and Tr1 cell, respectively). Th1 cells are considered mainly
proinﬂammatory and are central to development of cell-mediated immunity;
Th2 cells promote antibody production and humoral immunity; whereas
Th3 cells are mainly down-regulatory.
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Table 1 Deﬁning features of T-helper, T-regulatory, and unconventional T cell populations
T-helper cells Regulatory T cells
Th17 cell
Unconventional T cells
Th1 cell Th2 cell Th3 cell Tr1 cell Natural killer T cell
Mucosal-associated 
invariant T cell
T-cell receptor α-chain Heterogenous Heterogenous Heterogenous Heterogenous Heterogenous Semi-invariant 
(Vα14/24-Jα18)
Semi-invariant 
(Vα7.2/19-Jα33
T-cell receptor β-chain Heterogenous Heterogenous Heterogenous Heterogenous Heterogenous Limited (Vβ2,7,8/11) Limited (Vβ6/8)
Phenotype CD4+ CD4+ CD4+ and CD8+ CD4+ and CD8+ CD4+ CD4–CD8–or CD4+ CD4–CD8–
Cytokines IFN-γ , IL-2, & TNF-α IL-4, IL-5, IL-9, & IL-13 TGF-β IL-10 IL-17A, IL-17F, IL-22, 
IL-6, & TNF-α
IL-4 & IFN-γ TGF-β & IFN-γ
Location Blood, thymus, lymphoid 
organs, tissues
Blood, thymus, lymphoid 
organs, tissues
Gastric mucosa Blood, thymus, 
lymphoid organs
Intestinal lamina propria Thymus, spleen, liver, 
bone marrow, blood, 
gastric mucosa
Blood, intestinal 
lamina propria
Restriction MHC class II MHC class II MHC class II MHC class II MHC class II CD1d MR1
Ligands Peptide Peptide Peptide Peptide Peptide Endogenous and 
exogenous lipids
Possibly peptides
Function Immunity to intracellular 
bacteria and some viruses
Immunity to helminths 
and parasites
Immuno-regulatory, 
control of excessive 
responses to foreign 
antigen
Immuno-regulatory, 
control of excessive 
responses to foreign 
antigen
Immunity to 
extracellular bacteria
Anti-tumor, immuno-
regulatory
Potential immunity 
to oral pathogens 
Gut IgA secretion 
Oral tolerance
IFN, interferon; IL, interleukin; MHC, major histocompatibility complex; MR1, major histocompatibility complex class 1-related molecule; TGF, tumor growth factor; TNF, tumor necrosis factor.
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antigens [83]. Subsequently, it was shown that removal
of regulatory T cells (Treg cells, see below) restored the
proliferative response to H. pylori [84]. In the human
gastric mucosa, H. pylori induces recruitment of CD4+ and
CD8+ T cells [85] and murine studies have shown that the
gastric inflammation is T cell-dependent, as, experimen-
tally, H. pylori does not induce gastritis in T cell-deficient
mice [86]. Thus, there is evidence that T cell responses
to H. pylori antigens are detectable in many individuals
and that gastric T cell infiltration is important in disease
pathogenesis.
The mucosal inflammation induced by H. pylori is
believed caused by a polarization towards a Th1-dominated
T cell response. Freshly isolated lymphocytes from H. pylori-
infected mucosa were shown to have a Th1 cell phenotype
(i.e. secreting IFN-γ) [87], and studies in IL-4- and IFN-γ-
deficient mice confirmed the role of Th1 cells in perpetuating
the development of inflammation associated with H. pylori
infection [88]. Moreover, D’Elios et al. [89] showed that
H. pylori-specific T cells with a Th1 phenotype (i.e. secreting
IFN-γ) could be cloned from H. pylori-infected gastric
mucosa and, through the production of IFN-γ, are cyto-
toxic to gastric epithelial cells. The production of IL-8 by
infected gastric epithelial cells, which acts as a chemokine
for neutrophils and an activating factor, plays a significant
role in the initial response to H. pylori infection. Produced
in response to bacterial products by phagocytic cells, such
as neutrophils, the cytokine IL-12 is a potent inducer of
naïve T cell conversion to the Th1 phenotype [90], and
also neighbouring activated macrophages are potent
producers of inflammatory IL-1, IL-6, IL-8, and TNF-α.
Notably, the presence of H. pylori in gastric biopsies has
been associated with strong production of IL-12 [91] and
the concomitant presence of large numbers of Th1 cells
[92]. Furthermore, increased levels of IL-17 [93] and IL-18
[94] have been found in the H. pylori-infected gastric
mucosa. IL-18 is considered a strong promoter of Th1-cell
proliferation by induction of IFN-γ secretion [95], and
IL-17 can act as a potent inducer of neutrophil-recruiting
IL-8 secretion during H. pylori infection [93]. Interestingly,
the neutrophil-activating protein of H. pylori promotes the
expansion of IFN-γ-producing cells (i.e. the Th1 pheno-
type) in antigen-stimulated T cell cultures, while decreasing
the number of IL-4-secreting cells (i.e. the Th2 phenotype)
[96]. Thus, the secretion of all of these inflammatory
mediators creates a cytokine milieu that facilitates the
polarization of the T cell response to a Th1 phenotype. The
antigenic specificities of the T cell clones isolated from
the H. pylori-infected mucosa have been extensively
studied, and have revealed that CagA and H. pylori urease
are the immunodominant antigens. Indeed, the majority
of Th1 cell clones isolated from H. pylori-infected mucosa
are specific for CagA with prominent production of IFN-γ,
but not IL-4 [89]. Therefore, overall, there is an abundance
of evidence confirming the presence and pathogenic
potential of Th1 cells in H. pylori infection.
Polarization towards a Th1 cell cytokine profile can
contribute to development of peptic ulcers and more severe
mucosal pathology, while on the other hand, activation of
a Th2 cell response results in amelioration of the dyspeptic
symptoms. In particular, it has been suggested that the
concomitant production of Th2 cell cytokines like IL-4 is
protective against severe pathology, and curbs the detri-
mental effects of the Th1-related cytokines [80]. Consist-
ent with this, T cells cloned from antral biopsies of patients
with peptic ulcers associated with H. pylori infection
produced large amounts of IL-12, IFN-γ, and TNF-α in vitro,
but not IL-4 [97], whereas both IFN-γ and IL-4 were
secreted by T cells from patients with nonulcer gastritis
[89,98]. Moreover, in renal transplant patients receiving
Th1 cell immunosuppression, it has been reported that
peptic ulcers are absent from the gastric mucosa despite
the presence of colonization with H. pylori [99]. Therefore,
it has been deduced that an uncontrolled Th1 cell response
to H. pylori infection results in persistence of inflammation
and disease, whereas in contrast, a Th2-mediated response
reduces the proinflammatory immune effects. Further-
more, it is now generally accepted that development of
H. pylori-induced pathology largely depends on Th1
cell-mediated responses and Th1 cytokines [88,100–105].
This has been established in animal models using IL-4–/–
and IFN-γ–/– mice [88], IFN-γ neutralization in a mouse
model [100], adoptive transfer experiments in IL-4-deficient
mice [101] and mice defective in Th1-cell development
[103], as well as genetic evidence from human popula-
tions [104] and experiments on the modulation of the Th1
response from concurrent helminthic infection [102] and
Toxoplasma infection [105]. Nonetheless, although a Th2-
polarized response protects against such pathology, this
does not imply that Th2 cells are responsible for protection
against H. pylori infection after immunization [1]. Instead,
Th1-polarized, rather than Th2-polarized, H. pylori-specific
T cells recruit monocytes that can lead to elimination of
H. pylori locally in the gastric mucosa and be protective
against infection [106–108]. Akhiani et al. [106] observed
in animal models that protection following immunization
with H. pylori lysate was IL-12 dependent and mediated
by Th1 cells. Similarly, Hafsi et al. [107] found that mem-
brane preparations of H. pylori induced the Th1-polarized
response and could account for the specific adaptive
immune response. Nevertheless, although reducing the
bacterial load, the induced Th1 cells can play a role in post-
immunization gastritis [108].
Details of an important mechanism controlling Th1/Th2
polarization in H. pylori infection, and based on bacterial
variation, have emerged more recently. The dendritic
T cells and H. pylori O’Keeffe and Moran
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cell-specific surface receptor, ICAM-3 grabbing nonintegrin
(DC-SIGN, CD209), a C-type lectin, is found in gastric
lamina propria or close to the gastric lumen during H. pylori
infection [109] and can act as a ligand for the bacterium
[110]. H. pylori activates dendritic cells and promotes their
maturation in a cag PAI- and VacA-independent manner
[111]. H. pylori-activated dendritic cells preferentially
produce IL-12, and lesser amounts of IL-6 and IL-10, in
contrast to most other extracellular bacteria [112]. The
secreted IL-12, as well as H. pylori antigens [113], promotes
NK-cell activation and induces a Th1 cell response [107].
H. pylori variants that express Lewis blood group antigens,
which occur within the O-chain moiety of LPS [56], can
bind to DC-SIGN and enhance the production of IL-10
which promotes a Th2 cell response and blocking of Th1 cell
activation [110]. Since Lewis antigen expression is subject
to phase variation [114], a significant proportion of Lewis-
negative variants can occur within an isolate population
of bacteria. Thus, a polarized Th1-effect can change to a
mixed Th1–Th2 cell response through the extent of Lewis
antigen–DC–SIGN interaction [110], thereby modulating
the host response, and allowing a switch from an acute
infection response to one that will allow chronic infection.
In summary, there is significant evidence that suggests
that infection with H. pylori is associated with a polarized
T cell response. Upon recognition of H. pylori antigens, the
development of an uncontrolled Th1 cell response with
the secretion of proinflammatory cytokines is centrally
involved in promoting the chronicity of infection and
associated with development of the more severe H. pylori-
related pathologies. On the other hand, a Th2-mediated
response reduces the proinflammatory immune effects.
However, although inducing a post-immunization gastritis
[108] because of a local delayed-type hypersensitivity
response [100], evidence indicates that Th1 cells play a
protective role against H. pylori infection.
Th17 Cells
More recently, a novel subset of effector T cells, called
Th17cells because of their production of IL-17 [115], has
been deduced to play a prominent role in the development
of chronic inflammation associated with inflammatory
[116] and autoimmune disorders [117]. Th17 cells are a
distinct population of T cells (Table 1) that are induced
under the influence of IL-23 (a cytokine that shares
homology with IL-12) [118], as well as IL-6 and tumor
growth factor beta (TGF-β) [119]. Th17 cells are a subset
of CD4+ T cells but differ from Th1 and Th2 cells by not
expressing the Th1 transcription factor T-bet nor the Th2
transcription factor GATA-3 [120]. Nevertheless, Gocke
et al. [121] showed that administration of interfering
RNA specific for T-bet suppressed both Th1 and Th17
cells, thereby implying some role for T-bet in Th17 cell
differentiation.
The production of IL-17 by these T cells stimulates a
variety of cells including fibroblasts, endothelial cells,
epithelial cells, and macrophages to secrete chemokines
ultimately resulting in the recruitment of polymorphs,
including neutrophils [122]. Therefore, while IL-17 is
produced by cells of the adaptive response, this cytokine
can function as a potent activator of innate immunity, and
may participate in protective immunity against largely
noninvasive bacteria, such as H. pylori. Such a role for IL-17
has been demonstrated in host defense against other
bacteria, e.g. Klebsiella pneumoniae [123]. Likewise, human
and murine T cells produce IL-17 upon stimulation with
Borrelia burgdorferi [124] and Mycobacterium tuberculosis [125].
The emerging evidence also indicates a significant role
for IL-17 in the development of inflammation [116],
specifically, IL-17 induces expression of inflammatory
mediators like IL-6 and prostaglandins [126], and Th17 cells
have been implicated in the immunopathology associated
with chronic inflammation [127]. Notwithstanding that
the Th1-cytokine IFN-γ and the Th2-cytokine IL-4 inhibit
the development of Th17 cells [128], Th17 cells, and Treg
cells are likely to play antagonistic roles in chronic inflam-
mation in the gut, including that induced by H. pylori,
although TGF-β can induce the development of both
populations [119]. Nevertheless, the interrelationship
between Th17 cells and other effector T cell populations
and Treg cell populations remains to be fully elucidated.
Given the growing reports of the prominent association of
IL-17 with a variety of other bacterial infections, it is likely
that Th17 cells are involved in the response to H. pylori.
Furthermore, due to the secondary impact of IL-17 from
Th17 cells on neutrophil recruitment and the role of Th17
cells in chronic inflammation, it is apparent that Th17 cells
have a potential role to play in H. pylori-induced inflam-
mation, particularly because neutrophil influx and inflam-
mation chronicity are both hallmarks of this infection.
Clearly, however, a great deal further study is required to
elucidate the mechanisms of H. pylori interaction with
Th17 cells and the influence of these cells on the H. pylori-
associated immune response.
Regulatory T Cells
Notably, while there is evidence of an infiltration of IFN-γ-
producing cells into the infected gastric mucosa in H. pylori
infection, this is also accompanied by infiltration of TGF-
β-producing cells, thus suggesting that regulatory cytokines
secreted by regulatory cells may counteract the effects of
Th1 cells (i.e. IFN-γ producing) [129] (Fig. 1). In general,
effector mechanisms and the development of inflamma-
tion in response to infection are controlled by a variety
O’Keeffe and Moran T cells and H. pylori
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of different host suppressor mechanisms, including the
generation of antigen specific regulatory T cells, the Treg
cells (Table 1), whose existence has been the subject of
much debate for many decades, and which have been
reviewed extensively [130–133].
Phenotype and Function of Treg Cells
Treg cells can be isolated from mice and humans, and these
cells have the capacity to suppress the activation of CD4+
and CD8+ T cells, NK cells, and B cells in vivo and in vitro.
Treg cells are crucial for the maintenance of tolerance to
self-antigens, food antigens, and normal intestinal flora,
and for preventing the development of autoimmune
diseases, enhancing antitumor responses and controlling
infections (see reviews [130–133]).
Two major subpopulations of Treg cells, the so-called
natural and inducible populations, exist [134] (Fig. 2).
Natural Treg cells originate in the thymus and exit to the
periphery constituting between 5% and 10% of all T cells
[133,134]. On the other hand, Treg cells may be induced
or generated in the periphery upon antigenic stimulation
and under the influence of cytokines secreted by dendritic
cells [134]. Naturally occurring Treg cells were first identified
by Sakaguchi et al. in 1995 [135] as a population of CD4+
T cells constitutively expressing the surface marker CD25
(i.e. CD4+CD25+ T cells), and that suppressed and prevented
the development of T cell-mediated autoimmune disease
in mice. Subsequently, other investigators identified
additional markers associated with naturally occurring
Treg cells and these include low expression of CD45RB
[136], and expression of GITR [137] and CD134 (OX40)
[138]. Notwithstanding this, many of these markers are
not exclusively found on Treg cells. The expression of the
transcription factor forkhead box P3 (Foxp3) is considered
the most promising marker of natural Treg cells since
transfection of T cells with the foxp3 gene confers them
with intracellular regulatory activity [139].
The suppressive function of Treg cells is mediated via the
production of IL-10 as in the case of Treg cells named Tr1
cells [140], or TGF-β in the case of cells termed Th3 cells
[141] (Fig. 1). The properties of Tr1 and Th3 cells are listed
in Table 1. While Th2 cells also secrete IL-10 and may have
regulatory function, they are distinguishable from Tr1 cells
that do not secrete the characteristic Th2 cell cytokine,
IL-4 [141]. Also, populations of CD4+ Treg cells, CD8+ γδ T
cells [142], and NKT cells that are capable of secreting
IL-10 [143] may also be categorized as Treg cells.
H. pylori and Treg Cells
As H. pylori colonization provokes a state of lifelong
chronic infection [9], the concept that Treg cells are
involved in actively suppressing the host immune response
to H. pylori has been explored [84]. In support of this
concept, H. pylori [144] and the related H. felis [145] are
unable to persist in IL-10 knockout mice, and mice lacking
Treg cells, CD4+CD25+ [146], and CD25+Foxp3+ [147] cells
develop more severe gastritis while possessing reduced
H. pylori bacterial loads in the gastric mucosa. Initial studies
investigating the role of Treg cells in H. pylori infection
have focused on T cells isolated from peripheral blood.
Lundgren et al. [84] demonstrated that although stimu-
lation of peripheral blood CD4+ T cells from infected and
noninfected humans occurred with an antigenic pre-
paration of H. pylori in vitro, the memory T cells from
infected subjects responded less compared than those of
noninfected controls. Importantly, this nonresponsiveness
to H. pylori was abolished upon removal of CD4+CD25+
Treg cells, indicating the relevance of these Treg cells in
suppressing the proliferative response.
While these findings suggest an important role for Treg
cells in responsiveness to H. pylori, investigations at the site
of infection within the gastric mucosa are certainly of more
importance pathophysiologically. To address the role of
Treg cells at the site of H. pylori infection, Lundgren et al.
[148] later demonstrated the presence of Treg cells that
expressed the characteristic CD4+CD25+ T cell phenotype
Figure 2 Natural and inducible regulatory T cells. The markers CD25 and
Foxp3 (forkhead box P3) are expressed on natural regulatory T cell (Treg
cells) that matures from a precursor T-helper cell (Th0 cell) in the thymus.
Inducible regulatory T cells are generated in the periphery upon stimula-
tion of naïve CD4+CD25– and CD8+CD25– with antigen. These inducible cell
populations include Tr1 cells that secrete interleukin-10 (IL-10), Th3 cells
that secrete tumor growth factor-beta, and IL-10-secreting CD8+
regulatory T cells.
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and coexpressed high levels of Foxp3 mRNA. Moreover,
CD4+CD25+ Treg cells have been shown to home and
accumulate in the H. pylori-infected gastric mucosa [149],
particularly in tumor compared to tumor-free gastric
mucosa [150]. Hence, these pathogen-specific Treg cells
have been associated with chronic infections by H. pylori
and postulated to control the development of immuno-
pathology [150]. Notwithstanding that the precise
mechanisms of suppression have to be defined, suppression
of local immune responses to H. pylori in the gastric
mucosa may account for the persistence of the bacterial
load and chronicity of infection (Fig. 3). Duodenal ulcers
are considered to develop as a result of an increase in gastric
acid production in response to H. pylori antral infection
[151], ultimately leading to ulceration, whereas in contrast,
adenocarcinoma develops after pangastritis and potent
proinflammatory cytokine suppression of acid secretion
[152] leading to atrophy and intestinal metaplasia with
progression to malignant transformation [153]. It is likely
that alterations in local suppressor cells, such as Treg cells,
which control and regulate inflammation [133], as well as
bacterial colonization [130], are central to the develop-
ment of both of these diseases, and represents a hypothesis
worthy of further investigation.
Thus, while it has been postulated that pathogen-
specific Treg cells control and prevent the development of
immunopathology associated with infection [132], these
cells also may benefit the pathogen in helping to prolong
the chronicity of the infection by suppressing protective
immune responses. Such a phenomenon is seen in other
bacterial infections (e.g. Bordatella pertussis) where pathogen-
specific Treg cells suppress Th1 cell responses resulting in
persistence of infection [154]. A similar phenomenon may
also operate in other Helicobacter infections where Treg cells
were reported to be expanded in numbers during H. hepaticus
experimental infection but inhibited the development
of intestinal inflammation [155]. In the case of H. pylori,
the presence and activities of local gastric Treg cell
populations may have implications in the suppression of
protective immune responses and, thereby, contribute to
maintenance of a chronic state of infection (Fig. 3).
Unconventional or Innate T Cells
Despite studies to date having focused largely on analysis
of the response of classical T cells to H. pylori infection, the
extent and the effectiveness of the so-called unconven-
tional T cells within the gastric mucosa is likely to have an
equally important role in determining clinical outcome.
Besides conventional T cells that express T cell receptors
(TCRs) with a very diverse repertoire, there are two evolu-
tionarily conserved T cell subsets expressing invariant
antigen-specific TCRs which are generated by a particular
variable-joining (V-J) gene segment combination during
ontogeny. These are the CD1d-restricted NKT cells and the
mucosal-associated invariant T (MAIT) cells [156] (Table 1).
These invariant T cell populations are often classified as
innate cells because they display a memory T cell phenotype
in the absence of antigenic stimulation and they respond
rapidly to challenge [157].
NKT Cells and Microbial Immunity
The discovery of innate lymphocyte populations which
share the characteristics of NK cells and classical T cells has
generated great anticipation for better understanding early
responses of the immune system [158]. Like conventional
T cells, these NKT cells express a TCR but also coexpress
cell-surface receptors that are characteristic of the NK cell
lineage. In contrast to T cells, the majority of NKT cells
express an invariant TCR alpha chain, encoded by Vα14
and Jα18 genes paired with variable Vβ8, Vβ7, or Vβ2
genes [159] (Table 1). Furthermore, NKT cells recognize
glycolipid antigens presented by CD1d [160] which is
expressed on cells of hemopoietic origin (dendritic cells,
B cells, and T cells) as well as on gastrointestinal epithelial
cells [161]. With regard to function, NKT cells are activated
very early in an immune response and are capable of
activating a variety of cell types [162]. Upon stimulation
they rapidly produce both IL-4 and IFN-γ and, thereby,
influence the differentiation of T cells into either a Th1- or
Figure 3 Potential complex interactions in the gastric mucosa of effector
T cells, regulatory T cells, unconventional T cells, and Helicobacter pylori.
Key: ↑↑, expansion; ↓↓, inhibition; +/–, activation or inhibition; black arrow,
positive effect; gray arrow, negative effect, light grey arrow, effect unclear.
H. pylori activates T-helper-1 (Th1) cell proliferation, promotes, and
expands the numbers of regulatory T cells (Treg) cells, and inhibits T-helper-2
(Th2) cells. Certain populations of natural killer T (NKT) cells are activated
in response to H. pylori-derived molecules, whereas others are inhibited.
In turn activated NKT cells promote the expansion of Treg cells, while
activated Treg cells suppress the functional activities of Th1, Th2, and NKT
cells. Other interactions may exist. These include the responses of the
mucosal invariant T cell (MAIT) and Th17 cells (Th17) to H. pylori and potential
interrelationships between these populations and Th1, Th2, and Treg cells.
For example, the Th1-cytokine interferon-gamma and the Th2-cytokine
interleukin-4 inhibit the development of Th17 cells, whereas tumor growth
factor-beta (a Treg cell differentiator) promotes their development.
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a Th2-cytokine phenotype [163]. NKT cells display diverse
effector mechanisms participating in tumor surveillance,
regulation of autoimmune diseases, and in host defense
against bacteria, viruses and protozoa [164]. Defects in the
numbers and function of NKT cells have been reported in
a variety of human diseases including advanced cancer
[165], autoimmunity [166], and microbial infection [167].
NKT cells are activated by lipids such as α-galactosylce-
ramide (α-GalCer) [160], a marine sponge-derived
glycosphingolipid that has been used for anticancer
therapeutic purposes. Injection of mice with α-GalCer can
result in tumor rejection by a mechanism that is dependent
on IFN-γ production and/or antitumor cytotoxicity by NKT
cells [168]. An endogenous glycosphingolipid, isoglobotri-
hexosylceramide (iGB3) [169], is also capable of activating
NKT cells.
In addition to an antitumor role, NKT cells have been
shown to play a protective role in immunity to several
different bacterial infections. The mechanisms of how this
is achieved remain an open, but central, question. In some
cases, mice lacking NKT cells or CD1d are more susceptible
to certain pathogens. For example, Kumar et al. [170]
showed that a deficiency of NKT cells results in an impaired
immune response to B. burgdorferi. In other studies, NKT-
cell activation was shown to ameliorate disease as in the
case of lung infection with Pseudomonas aeruginosa [171] or
M. tuberculosis [172]. The target microbial lipid antigens
presented by CD1d to NKT cells have been the subject of
close scrutiny, and bacterially derived glycosylceramides
have been identified that can activate NKT cells. Mattner
et al. [173] reported evidence for antigen-specific activation
of NKT cells by glycosylceramides from Gram-negative,
LPS-negative alpha-proteobacteria such as Ehrlichia
muris and Sphingomonas capsulate, and Kinjo et al. [174]
showed that glycosphingolipids from Sphingomonas
served as targets for activation of NKT cells. Moreover,
activation of NKT cells by Gram-negative, LPS-positive
Salmonella typhimurium was mediated through an
endogenous lysosomal glycosphingolipid, iGB3 presented
by dendritic cells [169]. Though not identical, this bears
some resemblance to T cell CD1d-restricted recognition
of self-glycolipids presented on dendritic cells that have
been stimulated by a range of bacterial products, including
LPS [175].
H. pylori and NKT Cells
Novel populations of T cells expressing the NK cell
markers CD56, CD161, and CD94 have been observed in
antral biopsy specimens from adult human gastric mucosa
[176,177]. These NKT cells account for 14–35% of the
T-cell population in the epithelial layer and for 16–25% of
T cells in the lamina propria of the gastric mucosa [176].
This represents a sizeable T-cell subset suggesting a func-
tion for these cells in local immunity. Of note, marked
differences in the frequencies of NKT-cell populations
occur in H. pylori-infected individuals when compared
with noninfected controls [177,178]. The numbers of
these cells expressing CD56 and CD94 in both the
epithelium and the lamina propria layers of the mucosa
were reduced in infected individuals, whereas cells express-
ing CD161 were increased [177], indicating potential
functional differences between these NKT cells in response
to H. pylori infection. Moreover, in vitro stimulation with
differing H. pylori LPS preparations can result in expansion
or reduction in these NKT populations [178], further
emphasizing differing functional roles.
Given the abundance of NKT cell populations in the
normal antral mucosa, the observed changes in the
frequencies of NKT cell subsets in H. pylori infection, and
the central role of these T cells in antitumor immunity [179],
changes in the number and/or the functional responses of
NKT cells to H. pylori may influence the development of
localized malignancy in the gastric mucosa. Nonetheless,
as a T cell population in the gastric niche of H. pylori, NKT
cells are likely involved in the initial cellular response to
H. pylori and may play an important role in the outcome of
bacterial colonization [167] as seen with infections at
other body sites, such as the lungs [171].
As Treg cells and NKT cells are central to the immuno-
regulation required for controlling pathogenic autoreactivity
and for maintaining homeostasis following infection, their
interactions also raise issues pertinent in H. pylori infec-
tion. These populations of T cells share some similarities,
but are phenotypically and functionally different (Table 1).
Nevertheless, there are reports highlighting potential
cross-talk between these cells [180]. Specifically, NKT cells
have the potential to regulate the functional activities of
Treg cells through IL-2-dependent mechanisms [181];
the IL-2 produced by activated NKT cells can promote
proliferation and expansion of Treg cells, whilst having no
effect on the suppressive activities of these cells. On the
other hand, activation of NKT cells has been demonstrated
to control Treg cell function in autoimmunity [182].
Conversely, Treg cells can control the functional activities
of NKT cells by suppressing the proliferation, cytokine
secretion, and cytotoxic activities of these cells [183].
Thus, it can be speculated that NKT cells and Treg cells
reciprocally regulate each other in H. pylori-infected
mucosa (Fig. 3). Bearing in mind that Treg cells have a
suppressive role in antitumor immunity [184] and NKT
cells promote tumor surveillance [185], the direct effects,
as well as the interactions between these T cells, may greatly
influence the development of H. pylori-associated gastric
cancer. Hence, investigations examining the local activities
of NKT cells and Treg cells and their responses to infection
T cells and H. pylori O’Keeffe and Moran
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with H. pylori would greatly enhance our understanding of
immunity to this gastric pathogen and infection outcome.
MAIT Cells
MAIT cells are another group of phylogenetically con-
served T cells [186] (Table 1). They were first described by
Porcelli et al. [187], who found T-cells expressing another
invariant TCR alpha-chain, Vα7.2-Jα33, among human
peripheral blood T cells. MAIT cells are most abundant in
the intestinal mucosa, specifically in the lamina propria,
and are virtually absent from the intestinal epithelium
[188]. The restricting element for MAIT cells has been
identified as the monomorphic MHC class 1-related (MR1)
molecule [189]. MAIT cells are absent in mice deficient for
this molecule, but are present in mice deficient for MHC
class I and class II molecules and in CD1d-deficient mice
[190]. The function of MAIT cells is unknown, but their
preferential localization in the intestinal lamina propria
suggests that they are involved in host defense mechanisms
[188]. In particular, MAIT cells can have a role in defence
against orally acquired pathogens and in oral tolerance
[186]. Moreover, their interaction with other immune
cells in the gut could result in the polarization of the
immune response to a Th1, Th2, or a Th3 phenotype or in
controlling local IgA production [191], and would have
importance in influencing both the cellular and the
humoral responses in H. pylori infection. Importantly,
the high numbers of MAIT cells occurring in the human
gut and the invariance of their TCR alpha-chain suggests
that these cells have such important roles [188]. Though
not yet defined, a dysfunction of MAIT cells would affect
disease development, including those associated with
H. pylori infection.
One study has shown that α-mannosylceramide-
activated these cells [192], but the antigen-binding groove
appears unsuitable for binding hydrophobic lipids or
glycolipids, and is more likely suitable for binding hydro-
philic peptides [189]. Compared with colonized mice, MAIT
cells are undetectable in germ-free animals, indicating that
the presence of commensal bacteria appears to be essential
for the expansion of MAIT cells in the intestine after birth
[191]. Since commensal bacteria and those causing
chronic infections share properties [38] and mechanisms
[193] to subvert and modulate the immune response
and aid longterm colonization, whether infection with
H. pylori influences proliferation of MAIT cells remains an
open question (Fig. 3).
Concluding Remarks
In summary, infection with H. pylori results in the
development of robust innate and adaptive host immune
responses characterized by a marked inflammatory response
with an influx of neutrophils and lymphocytes [3,8].
However, this response seldom results in natural clearance
of infection. Moreover, it can be argued that much of the
pathology associated with H. pylori infection results from
the host’s immune response rather than the direct action
of the bacterium or its pathogenic factors. The innate
response towards H. pylori infection is an initial, rapid
response involving recognition of various PAMPs. SP-D
binding can play an important role in initial defense
against the infection, but once colonization becomes
established and bacterial interaction occurs with gastric
epithelial cells, the Nod1-mediated interaction would
appear more important for the induction of the inflam-
matory response than TLR4- or TLR5-mediated responses.
Although H. pylori molecules interact with TLR4 and TLR5
that are expressed in the stomach, these interactions are
of low activity, thereby allowing H. pylori colonization.
Subsequently, with infection progression, a substantial
inflammatory response to H. pylori can develop after the
infiltration of TLR2-expressing granulocytes and mono-
cytes into the infected gastric mucosa.
The adaptive immune response to H. pylori is delayed,
antigen-specific, and leads to the activation of T, B, and
memory cells, but is influenced by the innate immune
response. The humoral response is characterized by the
presence of large numbers of antibody-producing cells
and the T cell response is skewed toward Th1 cells. This
adaptive immune response is initiated and maintained
by monocytes and related cells because of their production
of IL-12 which induces differentiation of naïve T cells to
Th1 cells. Nevertheless, H. pylori neutrophil-activating
protein [96] and outer membrane preparations [194] are
capable of inducing this Th1-polarization, and there are
concomitant increases in the Th1-promoting cytokines,
IL-12, IL-17, and IL-18 during infection. The development
of an uncontrolled Th1 cell response with the secretion
of proinflammatory cytokines is centrally involved in
promoting the chronicity of H. pylori infection and is
associated with development of the more severe
H. pylori-related pathologies. Induction of a Th2-mediated
response reduces the proinflammatory immune effects.
Though inducing a postimmunization gastritis [108]
because of a local delayed-type hypersensitivity response
[100], evidence indicates that Th1 cells play a protective
role against H. pylori infection. As systemic adjuvants
commonly used in human vaccines, such as aluminium
hydroxide, induce Th2-type immune responses pre-
ferentially [195], for successful vaccine development a
challenge exists to utilize new adjuvants and develop
immunization protocols that would promote a Th1-type
immune response toward H. pylori infection in humans
[196].
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On the one hand, the ubiquity and duration of immune
recognition of H. pylori, but potential lifelong colonization
on the other hand, demonstrate the effectiveness of the
bacterium to evade, dampen, or inhibit host responses
contributing to immunity [13,38]. One such mechanism
of the bacterium is the secretion of a low-molecular-
weight protein from H. pylori which, although allowing
antigen-specific activation of T cells, is capable of inducing
cell cycle arrest of such cells [197]. Also, the inability to
clear H. pylori infection may be linked to the activation of
Treg cells which have the capacity to inhibit activation
of Th1 cells, thereby limiting mucosal damage but at the
same time prolonging the persistence of the pathogen.
Consistent with this hypothesis, increased numbers of
gastric CD4+Foxp3+ Treg cells have been found in the
H. pylori-infected mucosa and are capable of suppressing
H. pylori-induced Th1 cell proliferation and IFN-γ pro-
duction [150]. Thus, pathogen-specific regulatory T cells
can control and prevent the development of immuno-
pathology associated with H. pylori infection, but these
cells can also benefit the bacterium in helping to prolong
the chronicity of the infection by suppressing protective
immune responses. Given that H. pylori is a pathogen that
possesses several evasion strategies [13], the responses of the
selected T cell populations and subsets which recognize
H. pylori will determine the outcome of infection and
which other immune cells and mechanisms are mobilized
into defense.
Overall, there are a number of outstanding questions
concerning the interrelationships between the various
T-cell populations and their responses to H. pylori (Fig. 3).
As a T-cell population Th17 cells have be classified as part
of adaptive immunity, but they play an important role in
mobilization of acute inflammation and neutrophilic
responses to extracellular bacteria, as well as in main-
tenance of epithelial layer barrier integrity [120]. Already,
Th17 cells have been implicated in defense against
extracellular bacteria such as Klebsiella [123] and Citrobacter
[198]. Since IL-17 induces a neutrophilic influx [122] and
contributes to the development of chronic inflammation
[127] but also induces growth, differentiation, and junc-
tional integrity of epithelial cells, the potential role of this
cytokine and Th17 cells in response to H. pylori needs to be
explored, particularly in a defensive role at the epithelium
and in maintaining epithelial barrier integrity.
NKT cells are well-recognized cells of the immune
system through their capacity to rapidly kill targets and by
potent cytokine secretion without prior need for extensive
cell division. Through their invariant TCRs, NKT cells
preferentially recognize glycolipids and these cells have
been implicated in protective roles in a number of bacterial
infections [170–172]. It is likely that they play an impor-
tant role in H. pylori infection and that modulation of acyl
chain expression in H. pylori lipids could influence NKT cell
recognition or activation. Nonetheless, the relationship
between NKT cells and Treg cells in the gastric mucosa
requires examination. Since NKT cells promote cancer
surveillance [185], whereas Treg cells have a suppressive
role in such immunity [184], the possibility of interaction
between these T cells during H. pylori infection and their
influence on infection outcome remains an open question.
What possible roles do other innate T cells, such as MAIT
cells, have in the gastric mucosa? Are they involved in
maintenance of tolerance or do they contribute to the
development of pathology? Collectively, the intimate links
between Th1, Th2, and these other T-cell populations
remain to be defined. A clear understanding of the mech-
anisms that H. pylori may use to suppress these interactions
would give valuable insights into how this bacterium
counteracts the host immune responses to perpetuate
chronic infection and could reveal new strategies for
therapeutic exploitation.
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